Close Menu

NEW YORK – Thermo Fisher Scientific said on Thursday that it has teamed up with Janssen Biotech, a member of Johnson & Johnson's Janssen Pharmaceutical Companies, to develop a companion diagnostic test to support clinical trial enrollment of cancer patients.

Under the deal, scientists at Thermo Fisher and Janssen Research & Development will initially validate biomarkers for use with the Thermo Fisher Oncomine Dx Target Test to identify non-small cell lung cancer (NSCLC) patients for enrollment into clinical trials. The firms may add other cancer indications later on.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.